keyword
MENU ▼
Read by QxMD icon Read
search

cancer and venous thromboembolism

keyword
https://www.readbyqxmd.com/read/29451944/total-hip-arthroplasty-in-patients-with-avascular-necrosis-after-hematopoietic-stem-cell-transplantation
#1
Anita Vijapura, Harlan B Levine, Michele Donato, Mark A Hartzband, Melissa Baker, Gregg R Klein
The immunosuppressive regimens required for hematopoietic stem cell transplantation predispose recipients to complications, including avascular necrosis. Cancer-related comorbidities, immunosuppression, and poor bone quality theoretically increase the risk for perioperative medical complications, infection, and implant-related complications in total joint arthroplasty. This study reviewed 20 primary total hip arthroplasties for avascular necrosis in 14 patients. Outcomes were assessed at routine clinical visits and Harris hip scores were calculated...
February 16, 2018: Orthopedics
https://www.readbyqxmd.com/read/29443673/edoxaban-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer
#2
EDITORIAL
Jack Hirsh, Jeffrey S Ginsberg
No abstract text is available yet for this article.
February 15, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29439174/description-of-venous-thromboembolism-in-hospitalized-patients-with-metastatic-cancer-a-national-sample
#3
Kahee A Mohammed, Leslie Hinyard, Martin W Schoen, Christian J Geneus, Eric S Armbrecht, Fred R Buckhold, Thomas E Burroughs
Background: This study aimed to determine patient-, tumor-, and hospital-level characteristics associated with venous thromboembolism (VTE), and to assess the impact of VTE on in-hospital mortality and length of hospital stay in hospitalized patients with metastatic cancer. Methods: Using the Nationwide Inpatient Sample database, a cross-sectional analysis was performed of patients aged ≥18 years with at least 1 diagnosis of primary solid tumor and subsequent secondary or metastatic tumor between 2008 and 2013...
February 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29436450/lesson-of-the-month-2-pulmonary-embolism-in-a-patient-on-rivaroxaban-and-concurrent-carbamazepine
#4
Thomas Burden, Charlotte Thompson, Efstathios Bonanos, Andrew Rl Medford
A 71-year-old female with a history of pulmonary embolism treated with rivaroxaban presented with acute onset shortness of breath, chest pain and palpitations. Computed tomographic pulmonary angiography (CTPA) revealed multiple bilateral pulmonary emboli. The patient was concurrently prescribed carbamazepine and was later diagnosed with recurrence of breast cancer during the admission. We discuss common drug interactions pertinent to direct oral anticoagulants (DOACs) that can increase the risk of further venous thromboembolism...
February 2018: Clinical Medicine: Journal of the Royal College of Physicians of London
https://www.readbyqxmd.com/read/29434159/successful-application-of-edoxaban-in-the-treatment-of-venous-thromboembolism-recurrence-in-a-patient-with-non-small-cell-lung-cancer-after-tumor-shrinkage
#5
Tetsuaki Shoji, Hidenori Mizugaki, Yasuyuki Ikezawa, Megumi Furuta, Yuta Takashima, Hajime Kikuchi, Houman Goudarzi, Hajime Asahina, Junko Kikuchi, Eiki Kikuchi, Jun Sakakibara-Konishi, Naofumi Shinagawa, Ichizo Tsujino, Masaharu Nishimura
This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was initially used to control VTE before chemotherapy. However, switching UFH to warfarin or edoxaban, a novel oral anticoagulant (NOAC), failed. Chemotherapy was then administered to control the tumor which was thought to have been the main cause of VTE, which had been treated by UFH. After tumor shrinkage was achieved by chemotherapy, we were able to successfully switch from UFH to edoxaban...
February 9, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29427323/androgen-receptor-dampens-tissue-factor-expression-via-nf-%C3%AE%C2%BAb-and-egr1
#6
Bastian Hoesel, Marion Mussbacher, Burak Dikorman, Manuel Salzmann, Alice Assinger, Lena Hell, Johannes Thaler, José Basílio, Bernhard Moser, Ulrike Resch, Hannah Paar, Nigel Mackman, Johannes A Schmid
BACKGROUND: Prostate cancer is one of the leading causes of cancer death in men. Advanced prostate cancer is usually treated by androgen deprivation therapy (ADT), which aims at diminishing circulating testosterone to reduce cancer growth. There is growing evidence that ADT can increase the rate of venous thromboembolism (VTE) in prostate cancer patients. The tissue factor (TF) gene is one of the most important mediators of coagulation and VTE, but so far there is limited data on androgen receptor (AR) mediated TF gene expression...
February 10, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29420429/elevated-venous-thromboembolism-risk-following-colectomy-for-ibd-is-equal-to-those-for-colorectal-cancer-for-ninety-days-after-surgery
#7
Fadwa Ali, Sadeer G Al-Kindi, Jacqueline J Blank, Carrie Y Peterson, Kirk A Ludwig, Timothy J Ridolfi
BACKGROUND: The risk of postoperative venous thromboembolism is high in patients with colon cancer and IBD. Although The American Society of Colon and Rectal Surgeons suggests posthospital prophylaxis after surgery in patients with colon cancer, there are no such recommendations for patients with IBD. OBJECTIVE: This study aims to analyze the incidence and risk factors for postoperative venous thromboembolism. DESIGN: This was a retrospective review using the Explorys platform...
March 2018: Diseases of the Colon and Rectum
https://www.readbyqxmd.com/read/29419408/distinct-pathogenesis-of-pancreatic-cancer-microvesicle-associated-venous-thrombosis-identifies-new-antithrombotic-targets-in-vivo
#8
Konstantin Stark, Irene Schubert, Urjita Joshi, Badr Kilani, Parandis Hoseinpour, Manovriti Thakur, Petra Grünauer, Susanne Pfeiler, Tobias Schmidergall, Sven Stockhausen, Markus Bäumer, Sue Chandraratne, Marie-Luise von Brühl, Michael Lorenz, Raffaele Coletti, Sven Reese, Iina Laitinen, Sonja Maria Wörmann, Hana Algül, Christiane J Bruns, Jerry Ware, Nigel Mackman, Bernd Engelmann, Steffen Massberg
OBJECTIVE: Cancer patients are at high risk of developing deep venous thrombosis (DVT) and venous thromboembolism, a leading cause of mortality in this population. However, it is largely unclear how malignant tumors drive the prothrombotic cascade culminating in DVT. APPROACH AND RESULTS: Here, we addressed the pathophysiology of malignant DVT compared with nonmalignant DVT and focused on the role of tumor microvesicles as potential targets to prevent cancer-associated DVT...
February 1, 2018: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/29417408/comparative-outcomes-of-thrombocytopenic-acute-leukemic-patients-with-venous-thromboembolism-at-a-comprehensive-cancer-center
#9
Maliha Khan, Travis M Cox, Mohammed Nassif, Mohanad A Alzubaidi, Naveen Garg, Wei Qiao, Fleur M Aung, Thein Hlaing Oo, Cristhiam M Rojas-Hernandez
Patients with hematological malignancies often have severe thrombocytopenia, which poses problems when making thrombosis management decisions. A retrospective study was conducted to analyze the clinical outcomes associated with different management options in acute leukemic patients with thrombocytopenia (≤ 50 × 109/L) following an acute venous thromboembolic event. A total of 74 patients were divided into three treatment groups: observation only (n = 30); anticoagulation (n = 23); or inferior vena cava placement (n = 21)...
February 7, 2018: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/29409080/-prolonged-secondary-prevention-after-venous-thromboembolism
#10
Rupert Bauersachs
Recent studies: Shortly after discontinuation of the oral anticoagulation (OAC) there is a 2- to 3 fold increase in VTE recurrences. The risk for recurrence is particularly high in VTE events that occurred without provoking risk factor, with minor provoking factors and in cases with persistent risk factors such as active cancer.Guidance document for the categorization of risk factors for VTE: A recent guidance document defined underlying risk factors for the occurrence of VTE and categorized them into three groups...
February 2018: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29406795/venous-thromboembolism-risk-in-head-and-neck-cancer-significance-of-the-preoperative-platelet-to-lymphocyte-ratio
#11
Tristan Tham, Lauren Rahman, Christina Persaud, Caitlin Olson, Peter Costantino
Objective We aimed to investigate the association between the preoperative platelet-to-lymphocyte ratio (PLR) and venous thromboembolism (VTE) in patients with head and neck cancer (HNC) undergoing major surgery. Study Design Retrospective cohort study. Setting Academic tertiary hospital from 2011 to 2017. Subjects and Methods Patients with confirmed HNC undergoing major surgery were included in this study. The preoperative PLR was recorded for all patients. Known VTE risk factors, including Caprini score, age, sex, smoking, body mass index, prior VTE, and anticoagulation, were also recorded...
February 1, 2018: Otolaryngology—Head and Neck Surgery
https://www.readbyqxmd.com/read/29399521/thrombosis-in-cancer-patients-etiology-incidence-and-management
#12
REVIEW
Rahul A Sheth, Andrew Niekamp, Keith B Quencer, Fadi Shamoun, Martha-Gracia Knuttinen, Sailendra Naidu, Rahmi Oklu
Venous thromboembolism (VTE) is the second most common cause of mortality in cancer patients. The mechanisms of cancer-associated thrombosis (CAT), much like cancer itself, are multi-factorial and incompletely understood. Cancer type, stage, tumor-derived factors and genetics all affect CAT risk. Furthermore, cancer therapies as well as the indwelling vascular devices through which these therapies are delivered can increase the risk for CAT. In this review, we summarize mechanisms of hypercoagulability in cancer patients, patterns of thrombosis associated with cancer, current guidelines for the diagnosis and management of CAT, and important considerations regarding the placement of implantable vascular devices in the care of cancer patients with VTE...
December 2017: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/29399517/neutrophil-extracellular-traps-are-increased-in-cancer-patients-but-does-not-associate-with-venous-thrombosis
#13
Rahmi Oklu, Rahul A Sheth, Keith H K Wong, Amin H Jahromi, Hassan Albadawi
Background: A single center, prospective tissue-based study was conducted to investigate an association between neutrophil extracellular traps (NETs) and venous thromboembolic disease in patients with malignancy. Methods: Plasma was collected from 65 patients in which 27 were cancer patients and 38 were age-matched non-cancer patients. Plasma NETs, circulating free DNA (cfDNA), DNase-1, endonuclease-G, endonuclease activity and thrombin-antithrombin III (TAT) complex levels was quantified...
December 2017: Cardiovascular Diagnosis and Therapy
https://www.readbyqxmd.com/read/29397103/caprini-risk-model-decreases-venous-thromboembolism-rates-in-thoracic-surgery-cancer-patients
#14
Helene M Sterbling, Amy K Rosen, Krista J Hachey, Niru S Vellanki, Philip D Hewes, Sowmya R Rao, Emma Pinjic, Hiran C Fernando, Virginia R Litle
BACKGROUND: Extended postoperative chemoprophylaxis is effective in reducing venous thromboembolism (VTE) among general surgical patients. We hypothesized that implementation of the Caprini risk assessment model (RAM) would reduce VTE rates among patients undergoing lung and esophageal cancer surgery. METHODS: The Caprini RAM, consisting of patient risk stratification and extended postoperative chemoprophylaxis with low molecular weight heparin, was implemented on the thoracic surgery service at Boston Medical Center in July 2014...
January 31, 2018: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29396864/effectiveness-and-safety-of-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer
#15
Michael Blake Streiff, Dejan Milentijevic, Keith McCrae, Daniel Yannicelli, Jonathan Fortier, Winnie W Nelson, François Laliberté, Concetta Crivera, Patrick Lefebvre, Jeff Schein, Alok A Khorana
Anticoagulation is used to treat venous thromboembolism (VTE) in cancer patients, but may be associated with an increased risk of bleeding. VTE recurrence and major bleeding were assessed in cancer patients treated for VTE with the most currently prescribed anticoagulants in clinical practice. Newly diagnosed cancer patients (first VTE 1/1/2013-05/31/2015) who initiated rivaroxaban, low-molecular-weight heparin (LMWH), or warfarin were identified from Humana claims data and observed until end of eligibility or end of data availability...
February 3, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29395243/risk-prediction-of-cancer-associated-thrombosis-appraising-the-first-decade-and-developing-the-future
#16
Alok A Khorana, Charles W Francis
Cancer-associated venous thromboembolism (VTE) has major consequences for patients, including morbidity and risk of mortality. However, there is substantial variation in risk depending on a multitude of clinical risk factors and many cancer patients are at low risk for VTE. This critical concept of risk variation has led to efforts to identify patients at high or low risk for developing VTE. Our research group and others have focused on understanding and predicting risk of cancer-associated VTE. This narrative review describe research efforts conducted over the past decade, beginning with the 2008 publication of the first validated risk assessment tool in this setting...
January 26, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29389673/low-molecular-weight-heparin-versus-rivaroxaban-in-the-treatment-of-venous-thromboembolism-in-gastrointestinal-malignancies
#17
Hannah K Choe, Maria T De Sancho, Sunnie S Kim, Tong Dai, Manish A Shah
: Due to their ease of use, the direct oral anticoagulants (DOACs) are an attractive treatment option for cancer-associated venous thromboembolism (VTE) and have been readily adopted by many clinicians. A recent published study comparing a DOAC (edoxaban) to the current standard-of-care low molecular weight heparin dalteparin for the treatment of cancer-associated thrombosis showed that edoxaban was noninferior to dalteparin for recurrent VTE, but the risk of major bleeding was higher. We present three patients with high-risk gastrointestinal malignancies complicated by cancer-associated VTE with progression of thrombosis while treated with the oral direct Xa inhibitor rivaroxaban...
January 31, 2018: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/29383557/anemia-and-bleeding-in-patients-receiving-anticoagulant-therapy-for-venous-thromboembolism
#18
Amir Kuperman, Raquel López-Reyes, Lopez-Saez Juan Bosco, Alicia Lorenzo, Bascuñana José, Dominique Farge Bancel, María Alfonso, Marina Lumbierres, Galia Stemer, Manuel Monreal Bosch, Andrei Braester
In patients receiving anticoagulant therapy for venous thromboembolism (VTE), the important issue of anemia influence on the risk of bleeding has not been consistently studied. We used the large registry data RIETE (Registro Informatizado Enfermedad Tromboembólica) to compare the rate of major bleeding in patients receiving anticoagulant therapy for VTE according to the presence or absence of anemia at baseline. Patients with or without cancer were separately studied. Until August 2016, 63492 patients had been enrolled...
January 30, 2018: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/29378726/comparative-effectiveness-of-direct-oral-anticoagulants-and-warfarin-in-patients-with-cancer-and-atrial-fibrillation
#19
Surbhi Shah, Faye L Norby, Yvonne H Datta, Pamela L Lutsey, Richard F MacLehose, Lin Y Chen, Alvaro Alonso
Randomized clinical trials comparing direct oral anticoagulants (DOACs) to warfarin in cancer patients have not been performed. We evaluated the effectiveness and associated risk of DOACs vs warfarin, as well as comparisons of DOACs, in a large population of cancer patients with nonvalvular atrial fibrillation (AF). Using the MarketScan databases, we identified 16 096 AF patients (mean age, 74 years) initiating oral anticoagulant and being actively treated for cancer between 2010 and 2014. Anticoagulant users were matched by age, sex, enrollment date, and drug initiation date...
February 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/29376959/-clinical-experience-with-the-use-of-rivaroxaban-in-the-treatment-of-cancer-patients-with-venous-thrombosis
#20
P F Kravtsov, S E Katorkin, M A Melnicov
The urgency of the problem. The incidence of various thromboembolic complications in patients with oncopathology reaches 5-12%. When treating VTE in patients with oncology it is necessary to choose between two generally recognized alternatives. The recommended two-component scheme of the initiating phase of anticoagulant therapy with subsequent long-term admission of VKA is fraught with the development of clinically significant bleeding during the initial selection of the dose of warfarin and an increased risk of recurrence of VTE...
2018: Khirurgiia
keyword
keyword
39888
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"